Morinda officinalis-inulin composition and application thereof in renal fibrosis products

Abstract

The invention belongs to the technical field of biological medicines, and particularly relates to a morinda officinalis-synanthrin composition and application thereof in renal fibrosis products. The radix morindae officinalis-synanthrin composition provided by the invention is prepared from radix morindae officinalis polysaccharide, synanthrin and water, the synergistic effect of the two polysaccharides can be exerted, the physical and chemical properties and biological activity of the radix morindae officinalis-synanthrin composition can be improved, the metabolic rate of the kidney to urea nitrogen creatinine can be remarkably increased, the fibrosis positive area can be remarkably reduced, and the bioavailability of the radix morindae officinalis-synanthrin composition is improved. The traditional Chinese medicine composition has a remarkable effect on treating renal fibrosis diseases. The raw materials of the composition are based on natural polysaccharides, so that the composition has good safety and degradability, and meets the high requirement of the medical field on the safety of biological materials. Compared with an existing single component, the compound design can achieve the multi-target effect, the treatment effect is remarkably improved, and the compound medicine has the large market competitive advantage.

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and in particular relates to a Morinda officinalis-inulin composition and its use in a product for treating renal fibrosis. Background Art

[0002] Renal interstitial fibrosis (RIF) is a hallmark and ultimate outcome of various progressive chronic kidney diseases (CKD). Renal fibrosis is caused by the accumulation of connective tissue in the kidneys. This process gradually leads to structural and functional destruction of the renal tubules, glomeruli, and interstitium, thereby affecting the normal functioning of the kidneys.

[0003] In-depth research into the pathophysiological mechanisms of renal infarction (RIF) in recent years has revealed that the immune response plays a crucial role in the development and progression of renal infarction (RIF). Modulating the immune response may be a key pathway for altering the course of RIF. Immunoregulatory imbalance is closely associated with the development of RIF. In CKD, persistent immune activation leads to massive inflammatory cell infiltration, renal parenchymal cell damage, or fibroblast activation, promoting persistent renal fibrosis and ultimately, progression to chronic renal failure. During RIF, the immune response is often abnormally activated, resulting in significant changes in the renal immune environment. This persistent immune activation is caused by pathological inflammation and is closely associated with the involvement of multiple immune cells in the kidney. For example, the infiltration and persistent activation of immune cells such as T cells, B cells, macrophages, and dendritic cells promotes the exacerbation of the local inflammatory response. Immune cell infiltration and the cytokines and chemokines they secrete further exacerbate renal parenchymal cell damage and dysfunction. Therefore, modulating the renal immune response has become a potential therapeutic target for altering the course of RIF.

[0004] In recent years, research both domestically and internationally has focused on the immunomodulatory and renal protective effects of Morinda officinalis (MO). MO is a traditional Chinese medicine commonly used to nourish kidney yang and enhance immune function. Its active ingredients include polysaccharides, steroids, and flavonoids. Morinda officinalis polysaccharides (MOPs), one of its main active substances, have demonstrated significant immunomodulatory and renal protective potential. For example, Chinese patent CN108752497A discloses a method for preparing and using a Morinda officinalis aqueous extract, oligosaccharides, and polysaccharides. Specifically, the method involves extracting a Morinda officinalis aqueous extract and crude polysaccharides from the root of MO by water extraction. The crude polysaccharide is then separated to yield its oligosaccharide and polysaccharide components, which are then characterized. Experiments have shown that its water extract and crude polysaccharide can promote the proliferation of mouse spleen cells and cytokine secretion, promote the proliferation of human liver cells and reduce the damage to cells caused by toxic agents, inhibit the expression of hepatitis B surface antigen and core antigen, inhibit the proliferation of liver cancer cells and inhibit the damage caused by ConA to the liver and kidneys of mice, and have a protective effect on the kidneys.

[0005] However, it is worth noting that it is difficult to achieve comprehensive reconstruction of intestinal homeostasis and sustained maintenance of long-term remission based on a single-drug treatment strategy. From a pharmacological and physiological perspective, drugs face extremely complex and harsh physical and chemical environmental challenges during their transit through the gastrointestinal tract. The gastrointestinal tract is rich in a variety of digestive enzymes, such as trypsin and pancreatic amylase, which can enzymatically degrade the structure of drugs. The diversity and complexity of the intestinal flora should not be underestimated, and their metabolites and the bacteria themselves may interact with drugs, affecting drug activity. In addition, different sections of the gastrointestinal tract show significant pH gradient changes, from the highly acidic environment in the stomach to the weakly alkaline environment in the small intestine, which poses a severe test to the stability and solubility characteristics of the drug. In addition, intestinal peristalsis is rhythmic and propels at a fast speed, which shortens the effective residence time of the drug in the intestine, thereby adversely affecting the absorption and efficacy of the drug.

[0006] Therefore, providing a drug that can regulate the immune response and intestinal microbiome and deeply analyzing the relevant mechanism of action of the key active ingredients of the drug in the process of renal fibrosis can provide a material basis and translational value for the clinical treatment of renal fibrosis. Summary of the Invention

[0007] This invention addresses the problems of the existing technology and provides a Morinda officinalis-inulin composition and its use in renal fibrosis products. The composite gel has good biocompatibility and versatility, and can simultaneously intervene in the intestinal microenvironment and renal fibrosis, filling a gap in existing treatment methods.

[0008] To achieve the above object, the technical solution adopted by the present invention is as follows: The present invention provides a Morinda officinalis-inulin composition and application thereof in a product for treating renal fibrosis.

[0009] Furthermore, the Morinda officinalis-inulin composition consists of Morinda officinalis polysaccharide, inulin and water.

[0010] Furthermore, the Morinda officinalis-inulin composition comprises, by weight, 0.5-1.5 parts of Morinda officinalis polysaccharide, 7-12 parts of inulin and 5-15 parts of water.

[0011] Furthermore, the Morinda officinalis-inulin composition comprises, by weight, 0.5-1.5 parts of Morinda officinalis polysaccharide, 7-12 parts of inulin and 10 parts of water.

[0012] Furthermore, the preparation method of the Morinda officinalis-inulin composition comprises the following steps: S1. Mixing Morinda officinalis polysaccharide and inulin according to parts by weight to obtain a mixture; S2. Heat water and add the mixture obtained in step S1 to the water according to parts by weight; S3. Stirring until the mixture becomes homogeneous and viscous, cooling, and allowing to stand to obtain a Morinda officinalis-inulin composition.

[0013] Furthermore, the preparation method of Morinda officinalis polysaccharide described in step S1 comprises the following steps: (1) Slice Morinda officinalis and mix with water, perform reflux extraction, and collect the extract A; (2) Extract A is centrifuged to obtain supernatant A and Morinda officinalis residue; (3) Mixing the Morinda officinalis residue with water, performing reflux extraction, and collecting the extract B; (4) Extract B is centrifuged to obtain supernatant B. Supernatant A and supernatant B are mixed and ethanol is added so that the volume fraction of ethanol accounts for more than 80% of the total volume fraction. The mixture is allowed to settle for 24-48 hours and the precipitate is collected. (5) The precipitate is washed with ethanol, dialyzed, decolorized and deproteinized to obtain the Morinda officinalis polysaccharide.

[0014] Preferably, the ethanol is anhydrous ethanol.

[0015] Furthermore, the heating temperature in step S2 is 65°C-85°C.

[0016] Furthermore, the cooling temperature in step S3 is 20°C-30°C.

[0017] Furthermore, the standing temperature in step S3 is 0° C.-4° C.; and the standing time is ≥12 h.

[0018] Furthermore, the renal fibrosis product includes drugs for preventing or treating renal fibrosis.

[0019] Compared with the prior art, the present invention has the following beneficial effects: (1) The Morinda officinalis-inulin composition provided by the present invention combines Morinda officinalis polysaccharide with inulin, which can exert the synergistic effect of the two polysaccharides, improve the physical and chemical properties and biological activity of the hydrogel, significantly enhance the kidney's metabolic rate of urea nitrogen and creatinine, and significantly reduce the positive area of ​​fibrosis, and has a significant effect in treating renal fibrosis diseases.

[0020] (2) The Morinda officinalis-inulin composition provided by the present invention has good biocompatibility and multifunctionality. Its potential therapeutic effects in intestinal barrier repair, inflammation regulation, microbial regulation and renal fibrosis inhibition provide a new treatment option for clinical practice. It can intervene in the intestinal microenvironment and renal fibrosis at the same time, filling the gap in existing treatment methods.

[0021] (3) The Morinda officinalis-inulin composition provided by the present invention is based on natural polysaccharides and has good safety and degradability, meeting the high safety requirements of biomaterials in the medical field. Compared with existing single-component hydrogels, its composite design can achieve multi-target effects, significantly improving therapeutic effects and possessing a significant market competitive advantage. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] Figure 1 This is the standard curve of glucose.

[0023] Figure 2 This is a characterization diagram of the Morinda officinalis-inulin composition of Example 1; A in the figure shows the phenomenon of the Morinda officinalis-inulin composition being injected into water through a syringe; B shows the phenomenon of water at a 45° inclination angle; and C shows the phenomenon of the Morinda officinalis-inulin composition at a 45° inclination angle.

[0024] Figure 3 This is the FT-IR spectrum of the Morinda officinalis-inulin composition in Example 1.

[0025] Figure 4 This is the SEM scanning result of the Morinda officinalis-inulin composition in Example 1.

[0026] Figure 5 This is a graph showing the rheological test results of the Morinda officinalis-inulin composition in Example 1.

[0027] Figure 6Figure 2 is a graph of weight growth trend and kidney index; A in the figure is the weight growth trend from the beginning of modeling to sampling; B is the weight change of mice at the time of sampling compared with the beginning of modeling; C is the kidney index at the time of sampling; in the figure, ns means no significant difference between the groups; * means significant difference compared with the RIF model group, p < 0.05; ** means significant difference compared with the RIF model group, p < 0.01; *** means significant difference compared with the RIF model group, p < 0.001; **** means significant difference compared with the RIF model group, p < 0.0001; # means significant difference compared with the Morinda officinalis polysaccharide group, p < 0.05; ### means significant difference compared with the Morinda officinalis polysaccharide group, p < 0.001.

[0028] Figure 7 Figure 2 is a graph of serum biochemical indicators; A in the figure is a graph of serum creatinine indicators; B is a graph of serum urea nitrogen indicators; in the figure, ns represents no significant difference between the groups; * represents a significant difference compared with the RIF model group, p < 0.05; # represents a significant difference compared with the Morinda officinalis polysaccharide group, p < 0.05; ### represents a significant difference compared with the Morinda officinalis polysaccharide group, p < 0.001.

[0029] Figure 8 is a graph of urine biochemical indicators; A in the figure is a graph of urine protein indicators; B is a graph of urine creatinine indicators; C is a graph of urea nitrogen indicators; in the figure, ns represents no significant difference between the groups; * represents a significant difference compared with the RIF model group, p < 0.05; ** represents a significant difference compared with the RIF model group, p < 0.01; *** represents a significant difference compared with the RIF model group, p < 0.001; # represents a significant difference compared with the Morinda officinalis polysaccharide group, p < 0.05.

[0030] Figure 9 The diagram shows the histomorphological and pathological results. In Masson staining, the blue color indicates the positive area of ​​fibrosis, and the arrows indicate the glomerular morphology. DETAILED DESCRIPTION

[0031] The present invention is described below through specific embodiments to make the technical solution of the present invention easier to understand and grasp, but the present invention is not limited thereto. The described embodiments are only a part of the embodiments of the present invention, rather than all the embodiments.

[0032] The endpoints and any value of the scope disclosed in this article are not limited to this accurate scope or value, and these scopes or values ​​should be understood as comprising values ​​close to these scopes or values.For numerical range, between the endpoint values ​​of each scope, between the endpoint values ​​of each scope and a separate point value, and between the separate point value, can be combined with each other and obtain one or more new numerical ranges, and these numerical ranges should be considered as specifically disclosed in this article. Unless the context clearly indicates otherwise, the singular form "one", "a kind of" and "described" as used herein include singular and plural indicators. The numerical range stated by endpoint is included in all numerical values ​​and fractions within the corresponding range, and the stated endpoint.

[0033] Based on the embodiments of the present invention, all other embodiments obtained by persons of ordinary skill in the art without inventive effort shall fall within the scope of protection of the present invention. The experimental methods described in the following examples are conventional methods unless otherwise specified; the reagents and materials described are commercially available unless otherwise specified.

[0034] Example 1 1. Preparation of Morinda officinalis polysaccharide: Ultrapure water (100 g) and Morinda officinalis (100 g) slices were mixed and extracted under reflux at 90°C for 2 h. The extracted solution was centrifuged at 4000 rpm for 20 min, and the supernatant was harvested. This process was repeated for a second extraction and centrifugation. After multiple filtrations, the supernatants were combined. The resulting mixture was treated with anhydrous ethanol to an 80% alcohol content and allowed to stand at 4°C for 24 h to precipitate the crude polysaccharide.

[0035] The crude polysaccharide was washed twice with 95% ethanol and then dialyzed against distilled water (using a 3.5 kDa molecular weight cutoff). The polysaccharide was purified using activated carbon decolorization and the Savage method for protein removal (using a 1:2 volume ratio of Sevage reagent (n-butanol:chloroform, 1:4) to a 500 mg / ml polysaccharide solution, shaken for 20 minutes, centrifuged at 3000 rpm for 3 minutes, and the supernatant retained). The purified polysaccharide was lyophilized to an off-white powder, yielding Morinda officinalis polysaccharide.

[0036] 2. Preparation of Morinda officinalis-inulin composition: Combine 10g of inulin (purchased from Maclean, catalog number I811905-10g) and 0.8g of Morinda officinalis polysaccharide to obtain 10.8g of the mixture. Heat 10g of water to 72°C and slowly add the mixture. Mix with a magnetic stirrer until a homogeneous, viscous consistency forms. Allow the sample to cool to 26°C and stand at 4°C overnight (12 hours). This yields the Morinda officinalis-inulin composition.

[0037] Figure 2The gel morphology, injectability and tilt stability of the Morinda officinalis-inulin composition of Example 1. It can be seen that the Morinda officinalis-inulin composition has good injectability under visual observation, remains unchanged at a 45° tilt angle, and has high viscosity.

[0038] Example 2 1. Preparation of Morinda officinalis polysaccharide: the method is the same as that in Example 1.

[0039] 2. Preparation of Morinda officinalis-inulin composition: Combine 8g of inulin and 1.5g of Morinda officinalis polysaccharide to obtain 9.5g of the mixture. Heat 8g of water to 85°C and slowly add the mixture. Mix with a magnetic stirrer until a homogeneous, viscous consistency is achieved. Allow the sample to cool to 20°C and allow to stand at 4°C overnight. This will yield the Morinda officinalis-inulin composition.

[0040] Example 3 1. Preparation of Morinda officinalis polysaccharide: same as in Example 1.

[0041] 2. Preparation of Morinda officinalis-inulin composition: Combine 12g of inulin and 0.5g of Morinda officinalis polysaccharide to obtain 15.5g of the mixture. Heat 15g of water to 65°C and slowly add the mixture. Mix with a magnetic stirrer until a homogeneous, viscous consistency forms. Allow the sample to cool to 30°C and stand at 4°C overnight. This will yield the Morinda officinalis-inulin composition.

[0042] Effect Examples 1. Draw the glucose standard curve Take 10 mg of glucose reference substance, accurately weigh it, dissolve it in distilled water, and then transfer it to a 100 mL volumetric flask to make up to the volume to prepare a glucose reference substance stock solution with a concentration of 0.100 mg / mL.

[0043] The prepared glucose reference stock solution was diluted to the following concentrations: 0.01 mg / mL, 0.02 mg / mL, 0.03 mg / mL, 0.04 mg / mL, 0.05 mg / mL, 0.06 mg / mL, 0.08 mg / mL, 0.10 mg / mL. 1.0 mL was then pipetted into a test tube. 1.0 mL of 5% phenol reagent and 5.0 mL of 98% concentrated sulfuric acid were added, shaken, and boiled for 30 min. The absorbance (A) was measured at 490 nm using a UV spectrophotometer. A standard curve was drawn with glucose concentration (C) as the horizontal axis and absorbance (A) as the vertical axis. The standard curve is shown in Figure 2. Figure 1 shown.

[0044] 2. Determination of Morinda officinalis polysaccharide content Take Morinda officinalis polysaccharide and quantitatively redissolve it in ultrapure water. Determine the polysaccharide content in Morinda officinalis polysaccharide. The polysaccharide content is qualified if it is greater than 85%. The specific steps are as follows: Accurately weigh 0.2 g (B) of the Morinda officinalis polysaccharide prepared in Example 1 into a 100 mL volumetric flask. Dissolve it in distilled water and dilute to the mark. Remove 10 mL and transfer it to the 100 mL volumetric flask. Dilute to the mark again with distilled water. Then, pipette 1.0 mL into a test tube. Add 1.0 mL of 5% phenol reagent and 5.0 mL of concentrated sulfuric acid, shake well, and boil for 30 minutes. Measure the absorbance (A1) at 490 nm using a UV spectrophotometer. Substitute the A1 value into the linear regression equation of the standard curve to obtain the polysaccharide concentration (C1).

[0045] The absorbance A1 was measured three times and the average value was 1.406. Substituting it into the linear regression equation of the standard curve, the polysaccharide concentration C1 was obtained to be 0.1882 mg / mL. The polysaccharide content of the Morinda officinalis polysaccharide was calculated to be 94.1%. It can be seen that the polysaccharide content of the Morinda officinalis polysaccharide prepared in this embodiment of the present invention is greater than 85%, which is qualified.

[0046] 3. FT-IR spectroscopy measurement of Morinda officinalis-inulin composition The experiment was conducted using the KBr-disk method with a Nicolet iZ-10 spectrometer (Thermo Nicolet, USA). First, potassium bromide (KBr) powder was pre-dried at 104°C for 12 hours. Next, the Morinda officinalis-inulin gel (MI Gel) sample prepared in Example 1 was mixed with pre-dried KBr powder (100:1) in an agate mortar and pressed into 1 mm pellets. The results were obtained at 400 to 4000 cm -1 Collect spectra within the range.

[0047] The FT-IR spectrum of MI Gel sample is as follows: Figure 3 As shown, the test shows: 3368cm -1 The corresponding point is the OH stretching vibration absorption peak, and a broad absorption band is formed; 2931cm -1 The corresponding peak is the stretching vibration peak of CH3, CH2 or CH; 1419cm -1 The corresponding peak is the variable angle vibration peak of CH3, CH2 or CH; 1031cm -1 The corresponding peak is the stretching vibration peak of C-OH; 936cm -1 The corresponding peak is the symmetrical stretching vibration peak of COC; 1636cm -1The corresponding peak is the OH angle vibration peak, indicating that the sample contains a small amount of water; The above characteristic peaks can be used to determine the presence of sugar compounds in the MI Gel sample.

[0048] 4. SEM scanning of Morinda officinalis-inulin composition The Morinda officinalis-inulin composition sample prepared in Example 1 was coated with gold under vacuum and imaged using a scanning electron microscope at a magnification of 100 to 4000 times using an accelerating voltage of 5.0 kV.

[0049] Scanning electron microscopy (SEM) results are as follows Figure 4 As shown, it can be seen that the Morinda officinalis-inulin composition has a loose, porous, network-like, tightly connected structure, which is consistent with the general characteristics of polysaccharide gels.

[0050] 5. Rheological properties test of Morinda officinalis-inulin composition The rheometer was used to test the Morinda officinalis-inulin composition of Example 1 by amplitude test at fixed frequency; linear change of shear rate; and temperature sweep at fixed strain and frequency. Figure 5 As shown, a temperature sweep was performed between 0°C and 90°C. Strain-dependent oscillatory shear rheology was performed with a fixed frequency of 1 rad / s. Shear rates were varied from 0.01 to 100 s −1 The above is the rheological characteristics of the Morinda officinalis-inulin composition (the reference substance is deionized water).

[0051] 6. Therapeutic effect of Morinda officinalis-inulin combination on renal fibrosis (RIF) (1) Experimental animals Sixty-four 8-week-old male C57BL / 6J mice were purchased from Guangdong Ruige Biotechnology Co., Ltd. Mice were housed in an SPF environment at the Animal Experimental Center of Guangdong Pharmaceutical University with a 12-h light / dark cycle, a temperature of 20–25°C, and a humidity of 60 ± 5%. Animals had free access to food and water. All mice were acclimated to a diet for 1 week before the experiment. The experimental protocol and procedures were approved by the Animal Experimentation Ethics Committee of Guangdong Pharmaceutical University on October 16, 2023, and were in compliance with the Guide for the Care and Use of Laboratory Animals.

[0052] (2) Induced RIF model, grouping, and drug administration The experiment was divided into 8 groups, with 8 mice in each group: healthy control group (Control, Ctrl), RIF model group (RIF), positive control group (losartan, LOS), Example 1 group (MI Gel) and 2 single-drug control groups (treated with Morinda officinalis polysaccharide and inulin, respectively).

[0053] From weeks 1 to 5, all groups except the blank control group were fed a diet supplemented with 0.25% adenine. From weeks 6 to 11, all groups except the blank control group were fed a diet supplemented with 0.10% adenine, and treatment of the mice began.

[0054] The RIF model group and the healthy control group were gavaged with pure water (0.1 mL / d) (the administration volume for all treatment groups was controlled at 0.1 mL).

[0055] The positive control group was given 100 μL / D of losartan aqueous solution with a concentration of 30 mg / kg.

[0056] Group 1 of Example 1: Oral administration of the Morinda officinalis-inulin composition prepared in Example 1 at 100 μL / D.

[0057] Morinda officinalis polysaccharide group (MOPs): Oral administration of MOPs aqueous solution 100 μL / D (MOPs aqueous solution concentration was 200 mg / kg).

[0058] The inulin group (Lnulin) was orally administered with 100 μL / D of Lnulin aqueous solution, i.e., 3125 mg / kg / d of Lnulin.

[0059] Mice were euthanized at 11 weeks.

[0060] (3) Experimental results - weight change rate and kidney index The weight growth trend of the experimental animals from the beginning of modeling to sampling and the renal index at the time of sampling were recorded. Figure 6 shown. Figure 6 A is the weight growth trend from the beginning of modeling to sampling; B is the weight change of mice at the time of sampling compared with the beginning of modeling; C is the kidney index.

[0061] Except for the mice in the healthy control group, the body weight of the mice in other groups showed a downward trend in the first 5 weeks. After drug treatment, the body weight of the mice in Example 1 group, Example 2 group, Example 3 group, Morinda officinalis polysaccharide group, and inulin group continued to recover, indicating that the Morinda officinalis-inulin composition, Morinda officinalis polysaccharide, and inulin can all improve the weight loss caused by RIF, among which the Morinda officinalis-inulin composition has the most obvious improvement effect.

[0062] The renal index of mice in the RIF model group was significantly lower than that of mice in the healthy control group (p < 0.0001), indicating that the renal fibrosis model was successfully established. The renal index of mice in the Morinda officinalis-inulin combination group, Morinda officinalis polysaccharide group, and inulin group all increased to varying degrees, among which the renal index of the Morinda officinalis-inulin combination group had the best effect.

[0063] (4) Experimental results - biochemical indicators Twelve hours after the last administration, mice were bled by eye removal and centrifuged at 3000 rpm for 15 minutes to obtain serum. Serum urea nitrogen (BUN) and creatinine (Scr) were measured using biochemical marker detection kits.

[0064] Urine was collected from mice in metabolic cages 24 hours before the last dose. Urine protein, urea nitrogen, creatinine, and other biochemical indicators were measured using biochemical marker kits. The kits included a urea nitrogen kit (purchased from Nanjing Jiancheng, Cat. No. C013-2-1); a creatinine kit (purchased from Nanjing Jiancheng, Cat. No. C011-2-1); and a urine protein kit (purchased from Nanjing Jiancheng, Cat. No. C035-2-1).

[0065] Serum biochemical indicators such as Figure 7 As shown in the figure, urine biochemical indicators are as follows Figure 8 The test results showed that the Morinda officinalis-inulin combination significantly reduced serum creatinine and urea nitrogen levels; inhibited the increase of 24-hour proteinuria, and significantly enhanced the kidney's metabolic rate of urea nitrogen and creatinine.

[0066] (5) Experimental results - histomorphology and pathology Representative photographs of kidney and colon tissues were collected from mice euthanized on the last day of week 11. The tissues were fixed in 4% paraformaldehyde overnight at 4°C, embedded in paraffin, and cut into 4 μm sections. Glomerular structure was visualized using hematoxylin and eosin (HE) staining. Masson staining was used to assess the extent of renal fibrosis.

[0067] The results are as follows Figure 9 As shown, histomorphologically, the kidneys of mice in the RIF model group showed significant atrophy and fibrosis compared to the healthy control group, while the Morinda officinalis-inulin combination group showed an improvement trend. H&E staining revealed glomerular atrophy in RIF mice, which was alleviated by treatment with the Morinda officinalis-inulin combination. Masson staining showed a significant reduction in the fibrosis-positive area in the Morinda officinalis-inulin combination group.

[0068] Finally, it should be noted that the above content is only used to illustrate the technical solution of the present invention, rather than to limit the scope of protection of the present invention. Simple modifications or equivalent substitutions of the technical solution of the present invention by ordinary technicians in this field do not deviate from the essence and scope of the technical solution of the present invention.

Claims

1. A Morinda officinalis-inulin composition and its use in renal fibrosis products.

2. The use according to claim 1, characterized in that: The Morinda officinalis-inulin composition consists of Morinda officinalis polysaccharide, inulin and water.

3. The use according to claim 2, characterized in that: The Morinda officinalis-inulin composition comprises, by weight, 0.5-1.5 parts of Morinda officinalis polysaccharide, 7-12 parts of inulin and 5-15 parts of water.

4. The use according to claim 3, characterized in that: The Morinda officinalis-inulin composition comprises, by weight, 0.5-1.5 parts of Morinda officinalis polysaccharide, 8-12 parts of inulin and 10 parts of water.

5. The use according to claim 1, characterized in that: The preparation method of the Morinda officinalis-inulin composition comprises the following steps: S1. Mixing Morinda officinalis polysaccharide and inulin according to parts by weight to obtain a mixture; S2. Heat water and add the mixture obtained in step S1 to the water according to parts by weight; S3. Stirring until the mixture becomes homogeneous and viscous, cooling, and allowing to stand to obtain a Morinda officinalis-inulin composition.

6. The use according to claim 5, characterized in that: The preparation method of Morinda officinalis polysaccharide described in step S1 comprises the following steps: (1) Slice Morinda officinalis and mix with water, perform reflux extraction, and collect the extract A; (2) Extract A is centrifuged to obtain supernatant A and Morinda officinalis residue; (3) Mixing the Morinda officinalis residue with water, performing reflux extraction, and collecting the extract B; (4) Extract B is centrifuged to obtain supernatant B. Supernatant A and supernatant B are mixed and ethanol is added so that the volume fraction of ethanol accounts for more than 80% of the total volume fraction. The mixture is allowed to settle for 24-48 hours and the precipitate is collected. (5) The precipitate is washed with ethanol, dialyzed, decolorized and deproteinized to obtain the Morinda officinalis polysaccharide.

7. The use according to claim 5, characterized in that: The heating temperature in step S2 is 65°C-85°C.

8. The use according to claim 5, characterized in that: The cooling temperature in step S3 is 20°C-30°C.

9. The use according to claim 5, characterized in that: The standing temperature in step S3 is 0° C.-4° C.; and the standing time is ≥12 h.

10. The use according to claim 1, characterized in that: The renal fibrosis products include drugs for preventing or treating renal fibrosis.

Images